New eye drug faricimab aims to control wet AMD with fewer shots
Disease control
Not yet recruiting
This phase 4 trial will test the drug faricimab (Vabysmo) in 64 people with wet age-related macular degeneration (AMD). Participants will receive eye injections every 4 weeks for 4 doses, then a treat-and-extend schedule based on disease activity. The study also measures biomarke…
Phase: PHASE4 • Sponsor: Junyeop Lee • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC